Insights On Drug Development
-
Formulation And Process Challenges For A Needle-Shaped API
9/28/2026
Managing challenging active pharmaceutical ingredient crystal structures and choosing dry granulation over wet granulation requires strategic processing choices.
-
CMC Considerations For CRISPR And Next-Gen Technologies
9/24/2026
CMC considerations for CRISPR and next-generation gene editing technologies are examined through the lens of LETI-101, a preclinical AAV5-delivered CRISPR candidate targeting Huntington's disease.
-
Safety First: Considerations When Formulating High Potency Compounds
9/23/2026
Developing highly potent APIs comes with unique challenges. Explore strategies for managing risk, protecting personnel, and advancing programs with confidence.
-
Three Success Factors To Accelerate Your Program To Clinical Trial
9/23/2026
Accelerating clinical timelines starts with a strong foundation. Discover how smart development strategies can reduce risk, conserve resources, and support future scale-up.
-
Questions That Will Accelerate The Speed Of Your Program To Clinical
9/23/2026
The right early-stage strategy can prevent costly delays later. Explore key considerations for advancing programs to the clinic with confidence.
-
Spray Drying: The Key To Maximize Drug Solubility And Bioavailability
9/23/2026
Spray drying helps overcome formulation challenges by improving solubility, bioavailability, and particle performance for complex drug candidates.
-
4 Reasons Early-Phase Drug Development In The US Gives US Pharma A Competitive Edge
9/23/2026
Domestic development strategies can help reduce delays, improve communication, and support more efficient progress toward clinical milestones.
-
White Label Stocking: Enhancing Supply Chain Flexibility And Speed To Market
9/23/2026
The most efficient inventory may be the inventory you haven't labeled yet. See how white label stocking creates greater flexibility across markets.
-
From Lab To Launch: Cutting Time In Pharmaceutical Development
9/23/2026
What really accelerates drug development? Increasingly, it's the combination of AI, Quality by Design, and data-driven decision-making.
-
The Delicate Dance: When Phase-Appropriate Decisions Carry More Risk
9/23/2026
Early drug development demands speed, but some decisions carry long-term consequences. Learn which process and analytical choices require teams to look beyond the next milestone.